Enhanced ocular delivery of tacrolimus via cationic nanoliposomes: Mitigating inflammation and rebalancing Th17/Treg responses in dry eye disease
Source abstract
Abstract
Dry eye disease (DED) is a common ocular surface disorder characterized by persistent inflammation and immune imbalance, leading to visual impairment and substantial deterioration in quality of life. Although topical medications remain the mainstay of DED management, their therapeutic effectiveness is frequently limited by poor corneal penetration, low ocular bioavailability, and potential safety issues associated with long-term administration. To address this, we engineered a low-dose cationic tacrolimus nanoliposome delivery system (FK506 NLPs) designed to enhance ocular surface drug availability while targeting immune-inflammatory dysregulation. The positively charged NLPs exhibited prolonged corneal residence via mucoadhesion and improved drug permeation. In a murine model of DED, FK506 NLPs accelerated ocular surface repair, improved tear film stability, and preserved conjunctival goblet cells and lacrimal gland structure. Mechanistically, they suppressed the expression of key proinflammatory mediators in both corneal and lacrimal tissues and restored immune homeostasis by re-establishing the balance between Th17 and regulatory T cells. Importantly, FK506 NLPs also exhibited favorable in vivo biocompatibility. Taken together, these findings demonstrated that FK506 NLPs combined improved ocular delivery with coordinated anti-inflammatory and immunoregulatory effects, highlighting their potential as a promising therapeutic strategy for the management of DED.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Advanced Drug Delivery Systems · Corneal Surgery and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. TFOS DEWS III: diagnostic methodology10.1016/j.ajo.2025.05.033 ↗
2. Dry eye disease: an update in 202210.1001/jama.2021.19963 ↗
3. Epidemiology and risk factors of dry eye disease: considerations for clinical management10.3390/medicina60091458 ↗
4. ROS-responsive microneedle patches enable peri-lacrimal gland therapeutic administration for long-acting therapy of Sjögren's syndrome-related dry eye
5. A comparison between tacrolimus and cyclosporine as immunosuppression after renal transplantation in children, A meta-analysis and systematic review
6. Inflammation in dry eye disease: how do we break the cycle?10.1016/j.ophtha.2017.08.029 ↗
7. Autoimmunity in dry eye disease - an updated review of evidence on effector and memory Th17 cells in disease pathogenicity10.1016/j.autrev.2021.102933 ↗
8. Th17 cells in primary Sjögren's syndrome: pathogenicity and plasticity10.1016/j.jaut.2017.11.003 ↗
9. Harnessing the biology of regulatory T cells to treat disease10.1038/s41573-024-01089-x ↗
10. Th17 cells in primary Sjögren's syndrome negatively correlate with increased Roseburia and Coprococcus10.3389/fimmu.2022.974648 ↗
11. The ocular surface immune system through the eyes of aging10.1016/j.jtos.2021.02.007 ↗
12. FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention10.1016/j.pharmthera.2020.107623 ↗
13. Use of nuclear factor of activated T cell-regulated gene expression for monitoring immunosuppression with extended-release tacrolimus after liver Transplantation-A proof of concept10.3390/pharmaceutics16101317 ↗
14. Inflammation-triggered local drug release ameliorates colitis by inhibiting dendritic cell migration and Th1/Th17 differentiation10.1016/j.jconrel.2019.11.001 ↗
15. Regulatory T-Cell augmentation or Interleukin-17 inhibition prevents calcineurin inhibitor-induced hypertension in mice10.1161/HYPERTENSIONAHA.117.09374 ↗
16. Combination treatment with metformin and tacrolimus improves systemic immune cellular homeostasis by modulating treg and Th17 imbalance10.3389/fimmu.2020.581728 ↗
17. Concomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease10.3389/fimmu.2024.1326066 ↗
18. Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis10.1111/ajt.16505 ↗
19. Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation10.3350/cmh.2024.0451 ↗
20. Bidirectional immunoregulation of calcineurin inhibitor tacrolimus on FOXP3 transcription?10.1016/j.mehy.2010.09.011 ↗
21. The tacrolimus concentration-to-dose ratio is associated with kidney function in heart transplant recipients10.1002/bcp.70041 ↗
22. Therapeutic potentials of low-dose tacrolimus for aberrant endometrial features in polycystic ovary syndrome10.3390/ijms22062872 ↗
23. Assessment of therapeutic options for reducing alkali burn-induced corneal neovascularization and inflammation10.1016/j.advms.2015.10.003 ↗
24. An insight on ophthalmic drug delivery systems: focus on polymeric biomaterials-based carriers10.1016/j.jconrel.2023.08.041 ↗
25. Topical ocular drug delivery systems: innovations for an unmet need10.1016/j.exer.2022.109006 ↗
26. Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment10.1186/s11671-024-04086-6 ↗
27. Recent progress of nanomedicine in managing dry eye disease10.1016/j.aopr.2024.01.008 ↗
28. Current advances in niosomes applications for drug delivery and cancer treatment
29. Cell wall destruction and internal Cascade synergistic antifungal strategy for fungal keratitis
30. Multifunctional cerium oxide nanozyme for synergistic dry eye disease therapy10.1021/acsami.4c07390 ↗
31. Regenerative cerium oxide nanozymes alleviate oxidative stress for efficient dry eye disease treatment10.1093/rb/rbac070 ↗
32. Polymer-modified liposomes for drug delivery: from fundamentals to applications10.3390/pharmaceutics14040778 ↗
33. Biocompatible cationic 5-fluorouracil loaded elastic liposomes for ocular delivery: in vitro, ex vivo, and in vivo evaluation
34. Corneal mucin-targeting liposome nanoplatforms enable effective treatment of dry eye diseases by integrated regulation of ferroptosis and inflammation
35. Nanoceria-mediated cyclosporin A delivery for dry eye disease management through modulating immune–epithelial crosstalk10.1021/acsnano.3c11514 ↗
36. Nano-based drug delivery system: recent strategies for the treatment of ocular disease and future perspective10.2174/1872211314666191224115211 ↗
37. Regulatory T cell plasticity and stability and autoimmune diseases10.1007/s12016-018-8721-0 ↗
38. Exosomes from Limosilactobacillus fermentum ameliorate benzalkonium chloride-induced inflammation in conjunctival cells10.3390/ijms252212282 ↗
39. Role of CD4+ T helper cells in the development of BAC-induced dry eye syndrome in mice10.1167/iovs.62.1.25 ↗
40. A novel schirmer strip-based tear matrix metalloproteinase measurement in dry eye evaluation10.1016/j.jtos.2025.01.004 ↗
41. Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye10.1080/07853890.2023.2228192 ↗
42. Fosfenopril attenuates inflammatory response in diabetic dry eye models by inhibiting the TLR4/NF-κB/NLRP3 signaling pathway10.1167/iovs.65.6.2 ↗
43. Dry eye management: targeting the ocular surface microenvironment10.3390/ijms18071398 ↗
44. PPAR-α agonist fenofibrate suppressed the formation of ocular surface squamous metaplasia induced by topical benzalkonium chloride10.1167/iovs.61.3.54 ↗
45. The alterations of ocular surface metabolism and the related immunity inflammation in dry eye10.1016/j.aopr.2024.08.003 ↗
46. Pathogenesis and treatment of Sjogren's syndrome: review and update10.3389/fimmu.2023.1127417 ↗
47. Reduced intraepithelial corneal nerve density and sensitivity accompany desiccating stress and aging in C57BL/6 mice10.1016/j.exer.2018.01.024 ↗